+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07170293

Phase II Study of Tunlametinib HL-085 for Treating NRAS Mutant Advanced Non-melanoma Solid Tumors

Led by Tianjin Medical University Second Hospital · Updated on 2025-09-12

15

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the use of Tunlametinib HL-085 to treat patients with advanced metastatic non-melanoma solid tumors that have NRAS gene mutations and have not responded to other treatments. This open-label, single-arm phase II clinical trial aims to observe and evaluate the drugs effectiveness and safety, expecting that the treatment will achieve an objective response rate of about 20%. The study is sponsored by Tianjin Medical University Second Hospital and focuses on refractory solid tumors with NRAS mutations, which affect important cell signaling pathways involved in cancer development. Participants will receive Tunlametinib capsules as the study drug, taken twice daily in 21-day cycles. The dosing may be reduced from the initial dose to 9 mg or 6 mg twice daily if needed. The treatment continues until specific criteria for stopping are met. The study is designed as a single group trial without a placebo or comparison arm, focusing on patients with NRAS mutant non-melanoma refractory solid tumors. During the study, participants will be monitored for up to 24 months to assess tumor response and safety. Evaluations will include measuring the objective response rate, progression-free survival, duration of response, disease control rate, overall survival, and recording adverse events. Regular assessments and follow-ups will help researchers track treatment effects and participant health throughout the study period.

CONDITIONS

Brief Title

Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors

Research Team

H

Haitao Wang, Ph.D

J

Jinhuan Wang, Ph.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here